21 May 2009
What else differs cellular rejection grade 1a from 0? annexin v and bcl in elective biopsies received from heart transplant recipients
S Zeglen, J Nozynski, E Wozniak-Grygiel, M Zakliczynski, A Laszewska, M ZembalaAnn Transplant 2009; 14(1): 31-31 :: ID: 880312
Abstract
Background: Despite of morphologic differences between non-rejection (0 due to ISHLT scale) and moderate focal cellular rejection (1a, ISHLT) i.e. lymphocytes aggregation, the genetic and clinical differences in CARGO studies were not shown. Therefore the aim of the study was to compare the expression of selected antigens associated with apoptosis in heart transplant (HTx) recipients in the context of 0 and 1a cellular rejection. The expression of Annexin V, Bcl-2 (protective apoptotic activity), Bcl-xL (antiapoptotic activity) and Bcl-xS/L (other antiapoptotic mechanism) were assessed.
Material/Methods: 17 heart transplant patients were retrospectively included into the trial (2 women and 15 men, mean age 46.2±13.9 yr, BMI 25.7±3.2). 10 biopsies presented rejection 0 and next 10-1a (due to ISHLT scale) - group A and B, respectively. Endomyocardial biopsy specimens were processed using routine immunohistochemical method. The frozen sections were incubated with adequate anti-human antibodies from BioVision and Santa Cruz Biotechnology. The expression was assessed according to IHC method i.e. 0 - the lack of expression, 1 - trace, 2 - distinct and 3 - strong. The correlation was analyzed between particular molecules expression. Results: The significant increase of Bcl-2 expression together with rejection was observed. The expression of other antigens was also shown but without signs of any significant tendency. No correlation in group A was noted, on the contrary, in group B the significant strong and negative correlation between Bcl-2 and Bcl-xS/L was revealed.
Conclusions: Bcl-2 expression responds to the morphologic progression of
graft rejection and is opposing to Bcl-xS/L activity.
Keywords: Heart Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






